To Be or Not to 340B Blog

Legal Updates on the 340B Program

Contact

All fields are required.

Name
Email
Message
Please leave this field empty.

Δ

About this Blog

To Be Or Not To 340B is a blog dedicated to the 340B Drug Pricing Program and its related laws and regulations. Our experienced health law attorneys are your eyes and ears for updates in the program and the law that affect covered entities, contract pharmacies and manufacturers.

Stay Connected

Subscribe by Email

Your website url

Topics

Audits
Certification/Recertification
Compliance
Contract Pharmacies
Covered Entities
Diversion
Duplicate Discounts
Guidance
Legislation
Litigation
Manufacturers
Orphan Drugs

Continuing Changes in the 340B Space: New Restrictions and Shifting Alliances
The Current State of 340B and What to Expect in 2023
Brenda Shafer, Michael French and Richard Davis Author Law360 Article on Questions Related to Section 340B Drug Pricing
340B Program Changes on the Horizon? Start Planning Now for Potentially Seismic Impact of Upcoming Genesis Decision
UPDATE: U.S. Supreme Court Sides with 340B Hospitals in Significant $1.6 Billion Part B Drug Payment Ruling

Quarles & Brady Blogs

Protecting the Product
Franchise Insider
To Be or Not to 340B Blog

To Be or Not to 340B Blog

Quarles & Brady LLP

Chicago

Denver

Indianapolis

Madison

Milwaukee

Minneapolis

Naples

Phoenix

San Diego

Tampa

Tucson

Washington, D.C.

Stay Connected

Disclaimer |
Privacy Policy

About Quarles & Brady LLP

Quarles & Brady provides sophisticated legal services to clients across the world. We don't just counsel, but invest in the success of each, leading them toward the achievement of their business goals.